In August 2023, the U.S. Department of Health and Human Services announced the first 10 drugs covered under Medicare Part D ...
In a report released today, Jo Walton from UBS maintained a Hold rating on Novo Nordisk (0QIU – Research Report), with a price target of ...
Cantor Fitzgerald analyst Louise Chen maintained a Buy rating on Novo Nordisk (NVO – Research Report) yesterday and set a price target of ...
Novo Nordisk's shares fell nearly 5% on Friday after results from a Phase 2a trial of the Danish drugmaker's experimental ...
Ozempic, the blockbuster diabetes shot made by Novo Nordisk A/S, is “very likely ... The 15 drugs targeted for the next round are expected to be named by early next year, drawing widespread ...
The Nordisk Film & TV Fond has teamed with the Göteborg Film Festival to launch the Nordic Series Awards, a new award to honor Nordic drama series. The Nordic Series Award replaces the Nordisk ...
Ozempic maker Novo Nordisk (NVO) announced mixed results today for a phase 2 trial of an experimental weight loss pill that ...
Shares of Novo Nordisk NVO gained 4.2% on Sept. 11 after the company presented encouraging detailed efficacy data from the early-stage study of its new, investigational oral obesity pill ...
Novo Nordisk Just Took a $530 Million Step Onto Moderna's Turf. Here's What It Means for Both Stocks
On Sept. 16 Novo Nordisk (NYSE: NVO) and Korro Bio (NASDAQ: KRRO) announced that they'd be starting a new drug-development collaboration worth hundreds of millions of dollars, in an area that most ...
in a pre-IPO round, said people aware of the development. Investors including Quadria Capital and Denmark-based pharmaceutical major Novo Nordisk are among those interested in a minority stake and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback